ISRIB itself has not entered human clinical trials, and as of mid-2025, there are no registered studies dosing the original compound in people. The molecule’s poor water solubility and limited oral bioavailability made it impractical for clinical use in its original form. What has reached human testing are next-generation compounds inspired by ISRIB’s mechanism, most notably fosigotifator (ABBV-CLS-7262) and DNL343, both designed to activate the same molecular target while being easier to dose in patients. The story of ISRIB’s “progress” is really the story of these derivatives, and the results so far have been a mix of genuine biological proof-of-concept and sobering clinical disappointment.
What ISRIB Does at a Molecular Level
To understand why researchers have been so excited about ISRIB for over a decade, you need a brief picture of the pathway it targets. Cells have a built-in alarm system called the integrated stress response, or ISR, which activates when things go wrong. Viral infection, nutrient shortage, a buildup of misfolded proteins, or physical trauma to tissues can all trip this alarm. When it fires, cells dial down most protein production and ramp up a small set of stress-coping genes, essentially shifting into survival mode.1PubMed Central. The integrated stress response That response is protective in the short term. The problem arises when the ISR gets stuck in the “on” position, which appears to happen in traumatic brain injury, age-related cognitive decline, and several neurodegenerative diseases. Chronically suppressed protein synthesis in neurons can impair memory formation and synaptic function.
ISRIB works by stabilizing a protein complex called eIF2B, the enzyme that normally recharges the machinery cells need to start building new proteins. When the ISR is active, phosphorylated eIF2 acts as a brake on eIF2B. ISRIB essentially glues together two halves of the eIF2B complex into its fully active form, making it harder for the stress signal to shut protein production down.2PubMed Central. Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule Structural studies pinpointed where ISRIB binds: a deep pocket at the interface between two of eIF2B’s regulatory subunits, bridging the complex’s central symmetry axis.3PubMed Central. Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B This binding site became the blueprint for the clinical-stage drugs that followed.
The Preclinical Evidence That Drove So Much Excitement
ISRIB generated headlines because its effects in animal models were unusually striking, particularly in the brain. In two different mouse models of traumatic brain injury, ISRIB reversed hippocampus-dependent memory deficits even when the drug was given weeks after the initial injury. The cognitive improvements persisted after treatment ended, and suppressed long-term potentiation in the hippocampus was fully restored.4PubMed Central. Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury A follow-up study found that brief ISRIB treatment also reversed structural changes to dendritic spines in the cortex after concussive injury, along with the associated working-memory deficits.5PubMed Central. Aberrant cortical spine dynamics after concussive injury are reversed by integrated stress response inhibition
In aging, the results were similarly eye-catching. Old mice treated with ISRIB showed improved spatial and working memory, restored neuronal electrophysiological properties, increased dendritic spine density in the hippocampus, and reduced neuroinflammatory markers including interferon and T cell-related immune signatures.6PubMed Central. Small molecule cognitive enhancer reverses age-related memory decline in mice In vanishing white matter disease, a genetic condition caused by mutations that reduce eIF2B activity, ISRIB normalized gene-expression markers, improved brain white matter pathology, and enhanced motor function in mice.7PubMed Central. Vanishing white matter: deregulated integrated stress response as therapy target And in cell-based models of ALS, ISRIB reduced the formation of stress granules, protein-RNA clumps that some researchers believe contribute to motor neuron death, while still allowing parts of normal protein synthesis to continue.8PubMed. ALSUntangled #80: ISRIB (Integrated stress response InhiBitor)
The collective picture from preclinical work was tantalizing: a single compound that could rescue cognitive function in aging, head trauma, and genetic brain disease, sometimes after a surprisingly short course of treatment. Researchers involved in this work openly described it as one of the most promising therapeutic avenues for chronic cognitive deficits. But getting it into patients proved more complicated than the mouse data might have suggested.
Why the Original ISRIB Molecule Never Reached Patients
The gap between a powerful lab compound and a viable drug is often enormous, and ISRIB is a textbook example. The molecule is highly lipophilic with very low water solubility, which creates formulation headaches and limits how well it is absorbed when taken orally. Achieving reliable blood and brain levels in human-sized bodies at practical doses turned out to be a significant engineering challenge. Rather than pushing the original compound through the expensive gauntlet of clinical development, pharmaceutical teams chose to design new molecules that bind the same pocket on eIF2B but have better drug-like properties: higher solubility, a longer half-life, and more predictable absorption.
Two such compounds have advanced to human trials. Fosigotifator (originally called ABBV-CLS-7262), developed by Calico Life Sciences in partnership with AbbVie, was the first to enter clinical testing. DNL343, developed by Denali Therapeutics, took a parallel path. Both are eIF2B activators that share ISRIB’s core mechanism but differ in their chemical structures and pharmacokinetic profiles.
DNL343 in Human Trials
DNL343 completed Phase 1 testing in healthy volunteers and a Phase 1b trial in people with ALS. In the healthy-volunteer study, single doses ranging from 15 to 800 mg were tested, and a separate cohort received the drug daily for 14 days at doses from 45 mg to 260 mg. The compound demonstrated a half-life that supports once-daily dosing and showed good penetration into cerebrospinal fluid, an important benchmark for any drug aimed at the brain.9PubMed Central. Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial In the Phase 1b ALS study, 29 participants received either DNL343 at 100 mg or 200 mg daily, or placebo, for 28 days. The drug was generally well tolerated and reduced ISR biomarkers in both blood cells and cerebrospinal fluid, providing the first evidence in humans that this class of drug could engage its target in the central nervous system.9PubMed Central. Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial
DNL343 was subsequently evaluated as a regimen within the HEALEY ALS Platform Trial, a large multicenter trial design that tests different drugs against a shared placebo group. That study, conducted at 74 sites across the United States, ran from May 2023 through May 2025.10JAMA Network Open. DNL343 and Disease Progression in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial The earlier Phase 1b data had established a favorable safety profile, central nervous system penetrance, and evidence of target engagement, but whether engaging the target would actually slow ALS progression was the critical unanswered question heading into this larger study.
Fosigotifator and the Healey ALS Trial
Fosigotifator entered clinical development through a Phase 1 first-in-human study evaluating safety, tolerability, and food effects. The compound then moved into the HEALEY ALS Platform Trial in a Phase 2/3 study that enrolled about 300 participants, randomized roughly 3:1 to receive one of two doses of fosigotifator or placebo for 24 weeks. The primary endpoint was whether the drug slowed disease progression as measured by a standard functional rating scale for ALS, along with mortality.
The results, announced in January 2025, were largely disappointing. Fosigotifator at neither dose met the primary endpoint of delaying ALS progression. Key secondary endpoints, including respiratory function and quality of life, were also not significantly changed. There was, however, a secondary signal worth noting: in a prespecified analysis of muscle strength, the higher dose slowed upper extremity deterioration by about 32 percent and lower extremity deterioration by about 62 percent compared to placebo. Safety looked acceptable, with treatment-related side effects occurring at similar rates across treated and placebo groups. Whether the muscle-strength signal represents a meaningful biological effect or a statistical flicker in a failed trial remains debated.
Fosigotifator is also being studied in vanishing white matter disease, the genetic condition where eIF2B itself is defective due to mutations in its subunit proteins. An open-label Phase 1b/2 study in adults and children with VWM disease began in 2023, with a planned enrollment of 50 participants across three age groups receiving treatment for four years. That study is not expected to finish until 2027. In 2024, the FDA accepted fosigotifator into its START pilot program for rare disease therapeutics, and an expanded access program opened for patients with VWM disease and its severe variant, Cree leukoencephalopathy.
How to Interpret a Failed ALS Trial
ALS has been a graveyard for promising drugs. The disease progresses quickly, patient populations are heterogeneous, and the functional rating scales used as endpoints are blunt instruments that may not capture the kinds of cellular-level changes an ISR modulator could produce. A 24-week window may also be too short to see meaningful clinical benefit from a mechanism that works by restoring protein synthesis balance rather than directly halting neurodegeneration.
The muscle-strength signal with high-dose fosigotifator hints that something biological may be happening, but prespecified secondary analyses in trials that miss their primary endpoint need to be interpreted with extreme caution. The drug clearly engages its target in the human brain and reduces ISR biomarkers. What it has not demonstrated is that reducing ISR activation translates into slower disease progression in ALS within a clinically practical time frame. That could mean the mechanism is wrong for ALS, or it could mean the trial design was not optimized for this kind of drug. Researchers continue to debate both possibilities.
Safety Concerns With Blocking the Stress Response
The ISR exists for a reason. It is a conserved survival program that helps cells weather infection, nutrient deprivation, and the accumulation of damaged proteins. Turning it off pharmacologically raises obvious questions about what happens when cells lose that protective brake. If you suppress the stress response in a neuron that needs it or in a tissue that relies on it during infection, you could in theory cause more harm than good.
Several lines of evidence address this concern. First, ISRIB and its derivatives appear to operate within a defined window. When stress signals are modest, the drug overrides them and restores normal protein synthesis. But when stress is severe and the phosphorylation of the upstream signal is very high, ISRIB’s effect is limited. Studies in cells showed that ISRIB inhibits the ISR only when the stress signal stays below roughly 45 to 70 percent of maximum activation; above that threshold, the stress response breaks through regardless of the drug.11PubMed Central. Small molecule ISRIB suppresses the integrated stress response within a defined window of activation This built-in ceiling may explain why ISRIB appeared safe in animals despite targeting such a fundamental pathway: during genuine emergencies, the cellular alarm still sounds.
Second, in neurons exposed to endoplasmic reticulum stress, ISRIB relieved the general shutdown of protein production but preserved the selective translation of ATF4, the key stress-response transcription factor. In other words, ISRIB fine-tuned the response rather than demolishing it entirely, at least in neurons.12Cell Death & Disease. Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis That selectivity was not observed in glial cells, though, which hints that different cell types may respond to ISR inhibition in different ways.
The long-term safety picture in humans remains essentially unknown. One review noted that despite being proposed as a therapeutic approach over a decade ago, published data on ISRIB’s clinical safety profile remain scarce, with concerns that efficacy may be compromised by side effects.13PubMed. Maximizing ISRIB Potential Requires Addressing Specificity, Long-term Safety, and Disease-specific Considerations Because the ISR is active in nearly every tissue, systemic suppression carries predictable on-target risks: reduced stress tolerance in organs that produce large amounts of protein (like the pancreas and liver), altered metabolic adaptation, and potential effects on immune cells that rely on ISR activation during infection or inflammation.14Frontiers in Cell and Developmental Biology. Overcoming immunotherapy resistance in breast cancer: a novel strategy by targeting the integrated stress response Strategies proposed to manage these risks include intermittent dosing schedules, tissue-targeted delivery, and careful sequencing with other therapies.
The ISR in Cancer and Why That Complicates Things
The ISR is not just relevant to brain diseases. Cancer cells frequently hijack the stress response to survive hostile conditions inside tumors: low oxygen, nutrient scarcity, and the metabolic strain of rapid growth. By activating the ISR, tumor cells can reduce their overall metabolic demand while ramping up specific proteins that support survival, migration, and escape from immune surveillance.15PubMed. The two faces of the Integrated Stress Response in cancer progression and therapeutic strategies This makes ISR activation both a vulnerability and a tool for tumors.
In principle, blocking the ISR in cancer cells with ISRIB-like compounds could strip away one of their adaptive advantages and sensitize them to chemotherapy or immunotherapy. There is preclinical interest in this idea, and some researchers have explored ISRIB as a way to overcome treatment resistance in specific cancer types.16PubMed Central. The integrated stress response in cancer progression: a force for plasticity and resistance But the ISR’s role in cancer is genuinely dual: in some contexts it promotes tumor survival, while in others it triggers cell death. Blocking the pathway systemically might help in one tumor while hurting in another, or might suppress anti-tumor immune responses that themselves depend on ISR activation. This complexity has kept oncological applications firmly in the early research phase, well behind the neurological indications.
What “ISRIB for Cognitive Enhancement” Actually Means Right Now
Popular coverage of ISRIB has sometimes veered into breathless territory, describing it as a “memory pill” or “brain rejuvenation drug.” The mouse data on age-related cognitive decline are legitimately impressive, but no eIF2B activator has been tested in healthy older adults for cognitive enhancement, and there are no registered trials with that goal. Every human study to date has focused on serious disease: ALS, vanishing white matter disease, or early-phase safety in healthy volunteers. Cognitive enhancement in otherwise healthy people is a much harder regulatory path, requiring different trial designs and a much higher bar for safety, since you are asking healthy people to accept risk.
There is also a meaningful gap between “reversed age-related memory decline in mice” and “will improve your memory if you are 65 and starting to forget names.” Mouse cognition is measured through spatial navigation tasks and fear conditioning, which test hippocampal function specifically. Whether the same ISR-related mechanisms contribute to the kinds of everyday cognitive complaints older humans experience has not been established. The inflammatory and immune-related changes ISRIB reversed in old mouse brains are real and relevant, but they are one piece of a much larger puzzle of human brain aging.
Vanishing White Matter Disease as the Clearest Use Case
If any indication represents a near-ideal match for eIF2B activators, it is vanishing white matter disease. The condition is caused directly by loss-of-function mutations in eIF2B subunits, meaning the drug’s target and the disease’s cause are the same protein complex. The preclinical data showed that ISRIB normalized markers and improved pathology in VWM mice.7PubMed Central. Vanishing white matter: deregulated integrated stress response as therapy target Unlike ALS, where ISR overactivation is one of many pathological processes happening simultaneously, in VWM the ISR dysfunction is the central problem. Boosting the activity of a genetically hobbled eIF2B complex is about as direct a therapeutic rationale as you can get.
The ongoing Phase 1b/2 trial of fosigotifator for VWM disease will take years to read out, given the four-year treatment period and the slow progression of the disease in many patients. But this is the indication most likely to show whether eIF2B activation works in principle in humans. A clear positive signal in VWM would not prove the concept for TBI or aging, but it would validate that the molecular mechanism translates from mice to people, which is the foundational question hanging over this entire drug class.
The Biohacker Elephant in the Room
ISRIB is commercially available from chemical suppliers for research use, and online communities devoted to cognitive enhancement and longevity have discussed self-experimentation with the compound for years. This is worth mentioning because it is a real phenomenon, not because it is advisable. The research-grade material is not pharmaceutical-quality, the compound’s poor solubility makes accurate dosing at home extremely difficult, and there is no human safety data for the original ISRIB molecule at any dose in any population. The animal doses that produced cognitive benefits were carefully formulated and delivered under controlled conditions that are essentially impossible to replicate in a home setting.
The assumption driving much self-experimentation is that because ISRIB enhanced cognition in mice without obvious toxicity, it is probably safe enough to try. But “no obvious toxicity in mice over a few weeks” is a very low bar. Mice do not live long enough to reveal whether chronic ISR suppression increases cancer risk, impairs pancreatic function, or blunts immune responses to infections that develop slowly. The clinical derivatives exist precisely because pharmaceutical companies judged the original molecule’s properties inadequate for safe human use, even under medical supervision. Taking the parent compound without medical monitoring and without reliable dosing information adds layers of risk that the preclinical data cannot account for.